Table 2.

Demographic and pathologic data of the study cohort

Parameter	Overall (n = 49)	PCa with LNM (n = 12)	PCa without LNM (n = 37)	P value
Age (year)				0.446
Mean ± SD	68.39 ± 6.83	67.08 ± 6.61	68.81 ± 6.93
95% CI	66.43–70.35	62.88–71.28	66.50–71.12
Height (m)				0.810
Mean ± SD	1.66 ± 0.05	1.66 ± 0.03	1.66 ± 0.06
95% CI	1.64–1.67	1.64–1.68	1.64–1.68
Weight (kg)				0.933
Mean ± SD	62.63 ± 8.36	62.83 ± 9.79	62.57 ± 7.99
95% CI	60.23–65.03	56.61–69.05	59.90–65.23
BMI (kg/m2)				0.982
Mean ± SD	22.75 ± 2.67	22.74 ± 3.11	22.76 ± 2.56
95% CI	21.99–23.52	20.76–24.71	21.90–23.61
Serum PSA (ng/ml)				0.010
Mean ± SD	27.79 ± 34.08	62.76 ± 51.67	16.45 ± 13.90
95% CI	18.00–37.58	29.93–95.59	11.82–21.09
PSA density (ng/ml/ml)				0.006
Mean (median)	0.65 (0.40)	1.15 (1.16)	0.48 (0.37)
IQR	0.22–0.82	0.40–1.62	0.19–0.61
Time between MRI/MRE and biopsy (d)				0.832
Mean (median)	4(3)	5(4)	4(3)
IQR	1–6	1–7	1–6
Time between MRI/MRE and surgery (d)				0.880
Mean (median)	15 (13)	16 (14)	15 (13)
IQR	7–20	7–27	7–20
Biopsy Gleason grade groups (%)				0.001
1	13 (26.5)	1 (8.3)	12 (32.4)
2	10 (20.4)	0 (0)	10 (27.0)
3	9 (18.4)	2 (16.7)	7 (18.9)
4	10 (20.4)	5 (41.7)	5 (13.5)
5	7 (14.3)	4 (33.3)	3 (8.1)
RP Gleason grade groups (%)				0.006
1	8 (16.3)	0 (0)	8 (21.6)
2	13 (26.5)	1 (8.3)	12 (32.4)
3	8 (16.3)	2 (16.7)	6 (16.2)
4	10 (20.4)	5 (41.7)	5 (13.5)
5	10 (20.4)	4 (33.3)	6 (16.2)

PCa prostate cancer, LNM lymph node metastasis, SD standard deviation, CI confidence interval, BMI body mass index, PSA prostate specific antigen, IQR interquartile, RP radical prostatectomy, Percentages are referred to the total of patient of the correspondent population